FDA Approves Gilead Science's TRUVADA for HIV-1 Treatment
Combination of Emtricitabine and Tenofovir Disoproxil
11 Combinations Available
The U.S. Food and Drug Administration (FDA) has approved TRUVADA for the treatment of HIV-1 infection in adults and adolescents weighing at least 35 kg (77 lbs). TRUVADA is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil (TDF) in its salt form tenofovir disoproxil fumarate. TRUVADA is available in 11 combinations with other antiretroviral drugs for the treatment of HIV-1 infection.
Comments